Lactoferrin modulation of BCG-infected dendritic cell functions.
Lactoferrin, an 80-kDa iron-binding protein with immune modulating properties, is a unique adjuvant component able to enhance efficacy of the existing Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine to protect against murine model of tuberculosis. Although identified as having effects on macrophage presentation events, lactoferrin's capability to modulate dendritic cells (DCs) function when loaded with BCG antigens has not been previously recognized. In this study, the potential of lactoferrin to modulate surface expression of MHC II, CD80, CD86 and CD40 from bone marrow-derived dendritic cells (BMDCs) was examined. Generally, lactoferrin decreased pro-inflammatory cytokines [tumor necrosis factor (TNF)-alpha, IL-6 and IL-12p40] and chemokines [macrophage inflammatory protein (MIP)-1alpha and MIP-2] and increased regulatory cytokine, transforming growth factor-beta1 and a T-cell chemotatic factor, monocyte chemotactic protein-1, from uninfected or BCG-infected BMDCs. Culturing BCG-infected BMDCs with lactoferrin also enhanced their ability to respond to IFN-gamma activation through up-regulation of maturation markers: MHC I, MHC II and the ratio of CD86:CD80 surface expression. Furthermore, lactoferrin-exposed BCG-infected DCs increased stimulation of BCG-specific CD3(+)CD4(+) splenocytes, as defined by increasing IFN-gamma production. Finally, BCG-/lactoferrin-vaccinated mice possessed an increased pool of BCG antigen-specific IFN-gamma producing CD3(+)CD4(+)CD62L(-) splenocytes. These studies suggest a mechanism in which lactoferrin may exert adjuvant activity by enhancing DC function to promote generation of antigen-specific T cells.
Hwang
Shen-An
SA
Department of Pathology and Laboratory Medicine, Medical School, University of Texas-Houston Medical School, Houston, TX 77030, USA.
Actor
Jeffrey K
JK
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D018122:B7-1 Antigen / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D051940:B7-2 Antigen / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D007781:Lactoferrin / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009163:Mycobacterium bovis / Q000276:immunology; D014376:Tuberculosis / Q000517:prevention & control*
D000276:Adjuvants, Immunologic; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D001500:BCG Vaccine; D019013:CD40 Antigens; D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D007781:Lactoferrin
J Immunol. 2007 Aug 1;179(3):1825-33
17641049
Annu Rev Immunol. 2002;20:621-67
11861614
J Agric Food Chem. 2005 Oct 5;53(20):7673-80
16190615
Biochem Cell Biol. 2002;80(1):103-7
11911118
FASEB J. 2008 Aug;22(8):2747-57
18364398
Biochem Mol Biol Int. 1997 Sep;43(1):79-87
9315285
Med Microbiol Immunol. 2007 Sep;196(3):171-80
17377816
Nat Immunol. 2000 Oct;1(4):311-6
11017102
Vaccine. 2005 Mar 18;23(17-18):2109-14
15755580
J Immunol. 2002 Apr 15;168(8):3786-92
11937530
Postepy Hig Med Dosw (Online). 2007;61:261-7
17507874
J Immunol. 1999 Sep 1;163(5):2688-96
10453010
J Leukoc Biol. 2007 Oct;82(4):956-67
17675563
J Exp Med. 2002 Dec 2;196(11):1507-13
12461085
Haematologica. 1995 May-Jun;80(3):252-67
7672721
Expert Rev Vaccines. 2008 Jul;7(5):635-50
18564018
Infect Immun. 2005 Mar;73(3):1903-5
15731098
Int Immunopharmacol. 2004 Sep;4(9):1187-99
15251114
J Clin Invest. 1995 Mar;95(3):1370-6
7883984
Int Immunopharmacol. 2002 Mar;2(4):475-86
11962727
Br J Dermatol. 2001 Apr;144(4):715-25
11298528
Eur J Immunol. 1994 Apr;24(4):793-8
7908633
Int J Tuberc Lung Dis. 1998 Mar;2(3):200-7
9526191
J Cell Biochem. 2000 Sep 14;79(4):583-93
10996849
Crit Rev Immunol. 2003;23(1-2):83-107
12906261
J Immunol. 2005 Oct 15;175(8):5324-32
16210638
J Immunol. 2006 Apr 1;176(7):4323-30
16547269
Immunol Lett. 2006 Apr 15;104(1-2):70-5
16413062
J Immunol. 2008 May 15;180(10):6868-76
18453607
Clin Exp Immunol. 2003 May;132(2):352-9
12699428
Postepy Hig Med Dosw (Online). 2007;61:277-82
17507876
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10188-92
7901851
Immunol Lett. 2000 Nov 1;74(3):183-8
11064098
Vaccine. 2007 May 10;25(19):3742-51
17321015
Vaccine. 2004 Mar 29;22(11-12):1498-508
15063575
Vaccine. 2004 Feb 25;22(8):1063-71
15161084
Vaccine. 2007 Sep 17;25(37-38):6730-43
17698261
Infect Immun. 2004 Apr;72(4):2101-10
15039332
Int Immunopharmacol. 2005 Mar;5(3):591-9
15683854
Annu Rev Immunol. 2005;23:515-48
15771580
Immunobiology. 2002 Mar;205(1):120-31
11999341
J Immunol. 1998 Nov 1;161(9):4882-93
9794422
Immunol Cell Biol. 2005 Oct;83(5):549-53
16174106
Biochimie. 2009 Jan;91(1):76-85
18486627
Immunology. 2000 May;100(1):21-8
10809955
Int Immunol. 1999 Jun;11(6):979-86
10360972
Genome Biol. 2005;6(6):223
15960813
Immunol Rev. 1998 Oct;165:231-47
9850864
Microbiology (Reading). 2006 Dec;152(Pt 12):3765-3775
17159227
J Drug Target. 2008 May;16(4):282-93
18446607
Nat Rev Microbiol. 2005 Aug;3(8):656-62
16012514
Biochem Cell Biol. 2002;80(1):1-6
11908632
Immunology. 1995 Sep;86(1):122-7
7590872
Annu Rev Immunol. 2004;22:745-63
15032595
Infect Immun. 2008 Aug;76(8):3771-6
18519560
Annu Rev Immunol. 2006;24:99-146
16551245
Int Arch Allergy Immunol. 2006;140(1):53-72
16534219
Annu Rev Immunol. 1997;15:297-322
9143690
Immunity. 2004 Sep;21(3):401-13
15357951